Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives. Issue 9 (15th May 2017)

• Record Type: Journal Article
• Authors: Tajbakhsh, Amir; Mokhtari‐Zaer, Amin; Rezaee, Mehdi; Afzaljavan, Fahimeh; Rivandi, Mehdi; Hassanian, Seyed Mahdi; Ferns, Gordon A; Pasdar, Alireza; Avan, Amir
• Is Part Of: Journal of cellular biochemistry. Volume 118:Issue 9(2017)
• Page Start: 2502
• Page End: 2515
• Publication Date: 2017-05-15
• Subjects: BREAST CANCER -- BRAIN‐DERIVED NEUROTROPHIC FACTOR -- EPIGENETICS -- RISK FACTOR -- PHARMACOLOGICAL MODULATORS; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.25943
• Languages: English
• ISSNs: 0730-2312

Abstract

ABSTRACT: Brain‐derived neurotrophic factor (BDNF) is a potent neurotrophic factor that has been shown to stimulate breast cancer cell growth and metastasis via tyrosine kinase receptors TrkA, TrkB, and the p75 NTR death receptor. The aberrant activation of BDNF/TrkB pathways can modulate several signaling pathways, including Akt/PI3K, Jak/STAT, NF‐kB, UPAR/UPA, Wnt/β‐catenin, and VEGF pathways as well as the ER receptor. Several microRNAs have been identified that are involved in the modulation of BDNF/TrkB pathways. These include miR‐206, miR‐204, MiR‐200a/c, MiR‐210, MiR‐134, and MiR‐191; and these may be of value as prognostic and predictive biomarkers for detecting patients at high risk of developing breast cancer. It has been also been demonstrated that a high expression of genes involved in the BDNF pathway in breast cancer is associated with poor clinical outcome and reduced survival of patients. Several approaches have been developed for targeting this pathway, for example TKr inhibitors (AZD6918, CEP‐701) and RNA interference. The aim of the current review was to provide an overview of the role of BDNF/TrkB pathways in the pathogenesis of breast cancer and its value as a potential therapeutic target. J. Cell. Biochem. 118: 2502–2515, 2017. © 2017 Wiley Periodicals, Inc. Abstract : Brain‐derived neurotrophic factor (BDNF) is a potent neurotrophic factor that has been shown to stimulate breast cancer cell growth and metastasis via tyrosine kinase receptors TrkA, TrkB, and the p75NTR death receptor. Several microRNAs have been identified that are involved in the modulation of BDNF/TrkB pathways. These include miR‐206, miR‐204, MiR‐200a/c, MiR‐210, MiR‐134, and MiR‐191; and these may be of value as prognostic and predictive biomarkers for detecting patients at high risk of developing breast cancer. It has also been demonstrated that a high expression of genes involved in the BDNF pathway in breast cancer is associated with poor clinical outcome and reduced survival of patients. Several approaches have been developed for targeting this pathway including TKr inhibitors (AZD6918, CEP‐701) and RNA interference. In the current review the role of BDNF/TrkB pathways in the pathogenesis of breast cancer, which may be regarded as a potential therapeutic target, has been underlined.